

Prodigiosin



Nonylprodigiosin



Streptorubin B



Obatoclax

HA14-1 decreases Bcl-2 and Bcl-xl expression and increases the expression of p53, suggesting that this compound may provide therapeutic potential for the treatment of human cervical cancer.[181] Members of the antimycin A family, a group of closely related bis-lactones previously known as inhibitors of mitochondrial electron transfer, are also anti-apoptotic Bcl-2 inhibitors, although they have not reached the clinical stage yet.[182] Another anti-apoptotic Bcl-2 inhibitor is AT-101 [(–)-gossypol], which has entered phase I/II trials. It may have clinical utility in patients with CLL and high-risk features and to enhance radiation-induced apoptosis.[183]



HA14-1



Antimycin A_1: R = nC_4H_9
Antimycin A_3: R = nC_6H_{13}



AT-101 [(-)-Gossypol]

Some antisense oligonucleotides that reduce the expression of *BCL-2* genes are undergoing clinical trials.[184] One of them is oblimersen sodium (Genasense®), an 18-mer oligonucleotide that was the first agent targeting the Bcl-2 pathway to enter clinical trials. It has shown chemosensitizing effects and an